

A

- ABS. *See* Affiliation biobehavioral system
- ACC. *See* Anterior cingulate cortex; Attention control condition
- Acceptance and commitment therapy (ACT), 791
 adaptive behaviors, 791
 contingencies, focus, 791
 mechanism of action in social anxiety disorder, 791–792
 therapy, 792
- ACT. *See* Acceptance and commitment therapy
- ADIS-IV. *See* Anxiety Disorders Interview Schedule for DSM-IV
- Affiliation biobehavioral system (ABS), 601
 endocrine substrates, associated
 oxytocin, 601
 progesterone, 601
 neural association
 social exclusion, 601
 social rejection, 601
 survival chance
 key role in increasing, 601
- AG. *See* Agoraphobia
- Agoraphobia (AG)
 comorbidity with social anxiety disorder, 228
 misdiagnosis as social anxiety disorder, 47
 subscale assesses fear, 53
 symptoms of, 53
- Alcohol abuse, social anxiety disorder
 comorbidity, 244
 gender discrepancy, prevalence of, 244
 individuals, 47
- Alprazolam
 social anxiety disorder management, 626–627
- Ambiguous events interpretation, 490–495
 ecologically valid ambiguous stimuli, 491
 interpretation biases
 classification, 492
 offline, 492
 online, 492, 493
 studies, 493
 social anxiety, 494
 interpretation modification program (IMP), 494
 advantage, 494
 interpretation training, 494
 research, 494
 negative face stimuli, 492
 social anxious individuals (SAIs), 490
 characterization of, 490, 493, 495
 negative interpretation, 490
 vs. non-anxious individuals, 492
- γ -Aminobutyric acid (GABA)
 neuronal excitability, 383
 reuptake inhibitor, 352
 temperament role, 383
- AMP. *See* Attention modification program
- Amygdala
 across primate species, 421
 basolateral region, 422
 biological measures, temperament
 assessment, 427–430
 hyper-excitable, 424
 intercalated islands, 422
 prefrontal cortex connectivity, 342
 response uncertainty and activation, 419–420
 role in infant temperament, 421–424
 high-reactive infant, 422
 low-reactive infant, 423
 thalamus, 422
- ANS. *See* Autonomic nervous system
- Anterior cingulate cortex (ACC)
 creatine ratio, 359
 dorsal portions of, 336
 neuroimaging in social anxiety disorder
 emotion regulation, activation studies, 343–344
 functional neuroimaging, 339–340, 342–343, 352–354
 structure, 336
 posterior, 513
 rostral, 336
- Anticonvulsants, social anxiety disorder management
 gabapentin, 645
 levetiracetam, 646

- Anticonvulsants, social anxiety (*cont.*)
 - pregabalin, 645–646
 - tiagabine, 647
 - topiramate, 646
 - valporic acid, 647
 - Antidepressants
 - bupropion, 641
 - mirtazapine, 640
 - nefazodone, 641
 - reboxetine, 641
 - tricyclic antidepressants, 641
 - Antipsychotics, atypical, 647
 - social anxiety disorder management, 647
 - Anxiety disorders interview
 - schedule for DSM-IV (ADIS-IV), 48
 - current comorbidity, social anxiety disorder, 237
 - psychiatric disorders, 236
 - social anxiety evaluation, 48
 - Anxiety prevention
 - core feature, social anxiety, 318
 - meta-analysis, 318
 - social anxiety disorder (SAD)
 - modifiable risk and protective factors, strategies to address, 319
 - summary, 319
 - Anxiety-related syndromes, 4
 - Anxious symptomatology, risk factors in
 - development of
 - behavioral inhibition, 314
 - meta-analysis, 314
 - temperamental trait, 314
 - comorbid symptoms, severity of, 313
 - internalizing disorders, 313
 - etiology of, 313
 - heritability of, 313
 - negative life events, 313
 - parental psychopathology, 313
 - environmental, 313
 - genetic, 313
 - social phobia
 - empirically-based model, 313
 - summary, 316
 - APD. *See* Avoidant personality disorder
 - Attention. *See* Attentional biases
 - Attentional biases
 - causal role, 487–489
 - attention bias modification (ABM) groups, 488
 - attention control condition (ACC) groups, 488
 - mediational analyses, 488
 - treatments, 489
 - evidence, 484–485
 - dot-probe detection paradigm, 484
 - emotional Stroop paradigm, 484
 - vs. dot-probe detection paradigm, 485
 - facial expressions, 484
 - human attentional system, limited capacity, 484
 - probe detection task, 484
 - social anxiety individuals (SAIs), 484
 - color-naming task, 484
 - spatial cueing paradigms, 485
 - methods, assessing limitations, 485–486
 - electroencephalogram (EEG) recording, 486
 - event-related potentials (ERPs), 486
 - finding's interpretation, complications in, 485
 - psychophysiological measures, 486
 - standardized assessment procedures, lack of, 485
 - modification, 487–489
 - effect on anxiety, to examine, 487
 - threat/attentional control, 489
 - antisaccade task, 489
 - anxious individuals, 489
 - multi-session study, 489
 - probe detection task, modified version, 489
- Attentional processes
 - attention-training programs, 679
 - cognitive models of social anxiety disorder, 679
 - social anxiety treatment impact, 679–679
- Attention control condition (ACC), 679
 - attentional bias, 487
 - trains attention, 679
- Attention modification program (AMP)
 - intervention for social anxiety disorder, 690
- Autonomic nervous system (ANS)
 - parasympathetic system, 75
 - sympathetic system, 75
- Avoidant personality disorder (APD), 4
 - clinical, personality pathology of, 40
 - conceptualization of, 27
 - construct, empirical evidence, 36–37
 - course of social phobia (SP), 34
 - low remission rates, chronic, 34
 - overlap of GSP, 34
 - criteria for social phobia, 9
 - development of, 27
 - distinguishing features of, 15
 - DSM criteria for, 28

- DSM-III, 27
 - stimulated interest, 27
 - empirical evidence relationship with social anxiety disorder, 37–38
 - empirical findings, 38
 - exclusionary criterion, 9
 - findings on disability, 39
 - genetic findings, 39
 - longitudinal studies, social anxiety disorder, 39
 - outlined in the DSM-5, 14
 - overlap, 30
 - paranoid personality disorders, 27
 - pathology, 40
 - psychological treatments, social anxiety disorder, 34, 35
 - psychopharmacological treatment studies, social anxiety disorder studies, 34, 35
 - psychotherapeutic interventions, 40
 - relating persons, problem, 27
 - social anxiety disorder comparison, 30–30
 - social interactional component, 14
 - state effects, 36
 - state personality effects, 38–38
 - symptoms, 40
- B**
- BAT. *See* Behavioral Assessment Test
 - BDD. *See* Body dysmorphic disorder
 - BDNF. *See* Brain derived neurotrophic factor
 - Behavioral assessment test (BAT)
 - measurement, 211
 - performance sense, 198
 - role-play tests, 198
 - socially phobic individuals, 202
 - Behavioral avoidance, social anxiety treatment impact, 686–687
 - Behavioral avoidance test (BAT), 686–687
 - Behavioral inhibition (BI)
 - adolescence, level, 334
 - anxiety
 - prevention, 318
 - symptoms, 100
 - evidence of, 102
 - future anxious symptomology, 314
 - genetically stable traits, 314
 - interpersonal constraint, 458
 - social phobia, development of, 361
 - Behavioral inhibition system (BIS), anxiety role, 780
 - Behavioral ratings, performance quality comorbid avoidant personality disorder, 690
 - social anxiety treatment impact, 688–690
 - computer-assisted CBGT, 689
 - received rational-emotive therapy, 688
 - social behaviors, micro ratings, 688
 - Behavioral theory. *See also* Cognitive behavioral model
 - contemporary status in social anxiety and phobia
 - generalization of social anxiety disorder functional equivalence, 461–462
 - response generalization, 462–463
 - stimulus equivalence, 461
 - stimulus generalization, 460–461
 - initiation, 457–460
 - maintenance
 - behavioral cusps, 472–473
 - behavioral momentum, 473
 - delayed events, 466–467
 - matching law, 464–465
 - reinforcement amount and certainty, 466–470
 - rule-governed behavior, 465–466
 - signal detection, 470–471
 - therapeutic change, 472
 - models, overview of, 451–456
 - Belongingness changes, responses to popularity, 611
 - manipulation of, 611
 - non-socially anxious individuals, 611
 - positive social attention effects, 611
 - socially anxious individuals, 611
 - social exclusion, 610–611
 - interpersonal rejection, 610
 - online ball-tossing task, 611
 - profoundly affect, 610
 - social anxiety affects, 610
 - socially anxious individuals, 610
 - high, 610
 - low, 611
 - temperamentally shy children, 610
 - Benzodiazepines
 - alprazolam, 642
 - anxiolytic properties, 641
 - benefits, 643
 - bromazepam, 643
 - children and adolescents use, 648
 - clonazepam
 - efficacy of, 642
 - paroxetine, treatment augmentation of, 643
 - vs. alprazolam, 642
 - social anxiety disorder management, 643
 - standing-dose treatment, 641

- Beta-adrenergic blockers, social anxiety disorder management, 643–644, 755
- BFNE. *See* Brief Fear of Negative Evaluation Scale
- BI. *See* Behavioral inhibition
- Biological factors, social anxiety
amygdala, 259–263
brain/cognitive development, 258–259
genetic influence, 256–258
pediatric clinical syndromes, 256
puberty, 263–266
- Bipolar disorder, social anxiety disorder comorbidity, 240–240
- BIS. *See* Behavioral inhibition system
- Body dysmorphic disorder (BDD), 239–240
DSM-IV criteria, 239
shubo-kyofu, social anxiety disorder, 240
social anxiety disorder comorbidity, 4, 239–240
- Brain derived neurotrophic factor (BDNF)
depression prediction, temperament, 382
gene, allele possession, 382
- Brief Fear of Negative Evaluation Scale (BFNE), 681
- Brief social phobia scale (BSPS)
observer-rater instrument, 51
psychometric properties of, 51
- Brofaromine, social anxiety disorder management, 629
- Bromazepam, social anxiety disorder management, 643
- BSPS. *See* Brief Social Phobia Scale
- Bupropion, social anxiety disorder management, 641. *See also* Antidepressants
sustained-release (SR), 641
- Bupirone
social anxiety disorder management, 644–645
azapirone, 644
- C**
- CAMS. *See* Child-adolescent anxiety multimodal study
- Cannabidiol, social anxiety disorder management, 647
cannabis sativa plant, derived from, 647
- CBT. *See* Cognitive behavioral therapy
- Child-adolescent anxiety multimodal study (CAMS), 284
childhood anxiety disorders, treatment of, 284
cognitive behavioral therapy
combination of, 284
efficacy, 284
document availability, 284
participants of, 284
- Chronic shyness
adolescent onset, 103
age of onset, 102
areas of overlap, 102
attribution style, 101
behavioral inhibition (BI), 100
anxiety symptoms, 100
cognitive control, 100
development, 100–103
empirical findings, 101
maladaptive attributions, 101
negative stereotyping of, 100
observational learning, 100
one size fits all model, 100
private self-consciousness, 101
relationship of, 100
ruminative cycles, 101
shy adolescents, 101
self-consciousness, 101
skilled social behavior, 101
theory of, 101
thinking patterns, 101
vocabulary
scores, 100
skills, 100
- CIDI. *See* Composite International Diagnostic Interview
- Citalopram, social anxiety disorder management, 637–638
- Clinical epidemiological study, 38
- Clinical interview, social anxiety and phobia assessment
agoraphobia, 47
depression symptoms, 47
DSM-5 criteria, social anxiety disorder, 47
free-flowing approach, 46
goals, 46
interviewer-rated scales, 51–52
self-report measures, 52–53
instruments, 53
self-report questionnaires, 52
socially anxious individuals (SAIs), 47
structured interviews, 48–50
- Clinically useful social anxiety disorder outcome scale (CUSADOS), 60
- Clonazepam, social anxiety disorder management, 642

- Cognitive behavioral group therapy (CBGT), 662
 educational supportive group therapy, 691
 non-behavioral interventions, 691
 treatment dismantling study, 663
- Cognitive behavioral model. *See also*
 Behavioral theory
 anxiety response in social anxiety disorder
 behavioral symptoms, 713–714
 cognitive symptoms, 715
 physical symptoms, 714
 automatic thoughts, 276
 childhood social anxiety, 274
 combination, cognitive behavioral therapy, 284
 co-rumination, 275
 dysfunctional post-event processing, 275
 emotional dysregulation in social anxiety disorder, 718–720
 emotional expression in social anxiety disorder, 718–720
 evidence-based care, accessibility of, 282
 explicit threat-related associations, 276
 long-term memory, 275
 maladaptive cognitive feature, 276
 mental representation of self as seen by audience, 708
 meta-cognition, 277
 negative evaluation
 external indicators, 716
 probability and consequences, 712
 negative post-event processing, 275
 other-directed social schemas, 276
 perceived/anticipated audience, 706–708
 perceived internal cues, 715
 post-event processing, 717–718
 preferential allocation of attentional resources, 710–711
 psychological and physical comorbidities, 274
 self image and audience behavior, 709–710
 self representation as seen by audience
 vs. appraisal of audience's expected standard, 711–712
 social situation, 275
 vicious cycle, 716
- Cognitive behavioral therapy (CBT)
 childhood social phobia, 279
 cognitive enhancers, psychosocial treatment, 762–765
 combined pharmacotherapy, 757
 emotion regulation interventions, 521–522
 focus, 521
 nerve growth factor gene, 256
 pharmacological treatments, 755–756
 comparison for social anxiety disorder management
 individual trials, 758–761
 meta-analyses, 757
 psychosocial treatments, 753–754
 relative efficacy of, 284
 self-efficacy theory, 767
 social anxiety disorder management, 626–627
 treatment-related reduction, 340
- Cognitive bias, social anxiety disorder
 attention studies, 484–489
 interpretation bias, 490–495
 memory studies, 495–500
- Cognitive-somatic anxiety questionnaire (CSAQ), 62–62, 63
- Cognitive symptoms, social anxiety disorder
 attentional processes, 679–680
 beliefs, 667–674
 biased judgments, 667
 judgment and interpretation-biases, 674–678
 interpretation bias, 677–678
 subjective probabilities, 674–676
 non-anxious adults, 667
 sections, 667
 self-statements, 667–674
 endorsement methods, 670–673
 production methods, 670
 summary of treatments, intervention, 692
 treatment impact, 667–685
- Comorbidity in social anxiety disorder
 comment, 244–246
 future directions, 244–246
 using, DSM-III AND DSM-III-R criteria, 228–230
 using, DSM-IV criteria, 231–238
- Composite international diagnostic interview (CID)
 comorbidity DSM-IV disorders, 231
 structured interview, 50
 SP section of the scale, 50
 structured interview based, 50
 utility, clinical, 50
- Continuum model, social anxiety disorder
 fears, general population, 5
- Corticotrophin-releasing hormone (CRH)
 molecules, 380
 peptide, 334
 presence of, 385
 secretion of, 420

- Cortisol, activity in social anxiety disorder, 334–335
- CRH. *See* Corticotrophin-releasing hormone
- Cross-cultural assessment, social anxiety challenges, 151–152
- Cross-cultural expressions, social anxiety disorder comorbidity, 243–244
- ethnic and gender differences, 243
 - groups of individuals, 244
 - Latino immigrants, after 21 age, 244
 - Latino immigrants, before age of 21, 244
 - Latinos born in the United States, 244
 - non-Latino white Americans, 244
 - Iranian adults, psychiatric disorders, 243
 - non-Western countries, 243
- CSAQ. *See* Cognitive-somatic anxiety questionnaire
- Cultural and developmental considerations, social anxiety, 15–18
- CUSADOS. *See* Clinically useful social anxiety disorder outcome scale
- D**
- D-cycloserine (DCS), social anxiety disorder management, 647
- Developmental factors, social anxiety
- attachment, 267–268
 - temperament, 268–270
- Dexamethasone suppression test (DST), social anxiety disorder finding, 334–335
- Diagnostic and statistical manual (DSM)
- diagnostic issues, 27–30
 - behavior theory, 27
 - DSM criteria for social anxiety disorder, 28
 - DSM-III criteria, APD, 27
 - DSM III level, 27
 - DSM-III-R level, 29
 - DSM-IV, 30
 - DSM-V, 30
 - generalized social phobia (GSP), 29
 - low self esteem, APD criteria, 27
 - performance problems, 29
 - postulating one disorder (APD), internal image, 30
 - scope, 27
 - social situations, 27
 - social withdrawal, 27
 - mental disorders-5, 3, 47
 - schizoid personality disorder cluster, 34
 - social anxiety definitions
 - DSM-III, 9
 - DSM-III-R, 10
 - DSM-IV, 10
 - DSM-IV-TR, 10–10, 13–14
- Diagnostic nosology, social phobia, 9–11
- classifications, 9–11
 - clinically-based SAD research, 11
 - comorbid diagnosis
 - social phobia, 10
 - DSM-III, 9
 - DSM-III, advent, 9
 - DSM-III-R, publication, 10
 - DSM-IV-TR, children, 10
 - DSM-5, 10
 - DSM system, 11
 - ICD-X, 11
 - international classification of diseases (ICD), 11
 - neurobiological indices, 11
 - observable behaviors, 11
 - phobic neurosis category, 9
 - psychopathological behaviors, 10
 - psychopathological social anxiety, 9
- Disability profile (DP), 52
- Disciplines and subdisciplines, social anxiety, 19
- Disqualification of positive social experiences (DPSOS), 64
- Dopamine
- extraversion genetic association studies of DR4, 385
 - neuroimaging of system in social anxiety disorder, 356–357
 - temperament role, 384
- DP. *See* Disability profile
- DSM. *See* Diagnostic and statistical manual
- DST. *See* Dexamethasone suppression test
- Duloxetine, social anxiety disorder management, 640
- Dysthmic disorder, social anxiety disorder comorbidity, 230
- E**
- Eating disorders, social anxiety disorder comorbidity, 239
- EEG. *See* Electroencephalogram
- Electroencephalogram
- biological measures, temperament assessment, 427
- Embarrassment

- across cultures, 128
 - person's misbehavior, 128
 - wide-ranging consequences, 128
- antecedent events, 120–122
- behavioral sequelae, 126
- development of, 122–123
- feelings, 118
- fundamental cause of, 124–126
- individual differences, 123–124
- nature of, 118
 - awkward abashment, 118
 - unwanted evaluations, threat of, 118
- nonverbal behavior, 119
- physiology, 119
- reaction of others, 127–128
- reprise nature, 128–129
- social anxiety disorder comparison, 128–135
 - behavioral sequelae, 131–132
 - development, 132–133
 - distinguishment, embarrassment and social anxiety, 130
 - normality and abnormality, 133–134
 - phenomenology, 130–131
 - similarities of the states, 135
 - timing, 131
- social emotion, 117
- social life, desirable functions, 117
- unbecoming behavior, 117
- Emotional face processing, functional
 - neuroimaging in social anxiety disorder, 338–342
- Emotional signals, processing and expression
 - body and posture, 605–606
 - body collapse, competition situations, 606
 - non-verbal social cues, 605
- faces, 603–604
 - display of dominance, 604
 - emotional facial expressions (EFEs), 603
 - perception of, 603
 - threatening, 603
 - eye tracking studies, 604
 - smiles, positive stimuli, 604
- voices, 604–605
 - fundamental frequency of speech (mF0), 605
 - prosody, 604
- Emotional states, social anxiety disorder
 - general social anxiety, distributions of social avoidance and distress scale (SADS), 7
 - overlapping and contrasting, 6–8
 - personal report of confidence as a speaker scale (PRCS), 6
 - public speaking fear, 8
 - social fears, level, 6
 - specific-fear questionnaires, 8
- Emotion regulation interventions, social anxiety disorder. *See* Cognitive behavioral therapy; Mindfulness-based stress reduction
- Emotion regulation, social anxiety disorder
 - attentional deployment, 515, 519
 - distraction method, 519
 - gross process model, 518, 519
 - rumination, 519
 - cognitive change, 515, 520
 - behavioral studies, 520
 - cognitive reappraisal, 520
 - reappraisal self-efficacy, 520
 - emotional episode, 515
 - process model, 515
 - psychological flexibility, 514
 - refers to, 515
 - response modulation, 520–521
 - associated with, 521
 - situation modification, 515, 518–519
 - gross process model, 518
 - safety behaviors, 519
 - situation selection, 515, 517–518
 - gross process model, 517, 518
 - measurement of, 518
 - strategies, 515
 - adaptive, 516, 517
 - gross process model, 516, 518
 - maladaptive, 516, 517
- Emotions, social anxiety disorder
 - attention-training procedures, 513
 - cognitive models, 513
 - emotional reactivity, 513
 - exaggerated, 514
 - neuroimaging studies, 514
 - spans, 513
 - fMRI studies, brain responses, 514
 - modal model, 512
- EOS. *See* Estimations of others scale
- ERP. *See* Event-related potential
- Escape. *See* Behavioral avoidance
- Escitalopram
 - children and adolescents use, 649
 - social anxiety disorder management, 637–638
- Estimations of others scale (EOS), 105

- Event-related potential (ERP), social anxiety disorder studies, 362, 429, 486
- Evidence-based treatment, social anxiety
- affords in-session, 279
 - child-adolescent anxiety multimodal study (CAMS), 284
 - cognitive-behavioral treatment, skill-building phase, 278
 - cognitive bias modification of interpretations (CBM-I), 282
 - exposure-based
 - tasks, 279
 - treatments, 279
 - in-vivo exercises, 282
 - launching emerging adults program (LEAP), 281
 - out-of-session exposures, 278
 - parental over-involvement, 282
 - problem-solving strategies, 278
 - psychopharmacologic interventions
 - evaluation, 284
 - psychosocial treatment, 277
 - 20-session LEAP intervention, 282
 - skill-building treatment, 278
 - transition-focused CBT protocol, 281
 - treatment builds, exposure phase, 278
- F**
- Fear and avoidance of eye contact, social anxiety theoretically measured components, 64
- Fear of embarrassment, measurement, 64
- Fear of negative evaluation (FNE)
- 30-item true-false self-report measure, 60
 - overview in social anxiety disorder, 60–61, 471
 - treatment impact, 681–685
- Fear of negative evaluation scale (FNES), 60–61, 471, 681
- overview in social anxiety disorder, 60–61
- Fear of positive evaluation scale (FPES), 63, 563–564, 712
- Fear questionnaire (FQ), 56–57
- anxiety disorder general measure, 56–57
 - good discriminate validity, 57
 - high test-retest reliability, 57
 - 15 items designed, 57
 - primary fear, 56
 - screening tool, 56
- Fluoxetine
- children and adolescents use, 648–650
 - cognitive behavioral therapy comparison for social anxiety disorder management, 638
 - social anxiety disorder management, 638–639
- Fluvoxamine
- children and adolescents use, 649
 - social anxiety disorder management, 638
- FMPS. *See* Frost multidimensional perfectionism scale
- fMRI. *See* Functional magnetic resonance imaging
- FNE. *See* Fear of negative evaluation
- FNES. *See* Fear of negative evaluation scale
- FPE. *See* Fear of positive evaluation
- FPES. *See* Fear of positive evaluation scale
- FQ. *See* Fear questionnaire
- FRIENDS prevention programs, 321–325
- anxiety early intervention and prevention, 323
 - children at anxiety risk, 325
 - follow-up, 325
 - cognitive behavioral therapy, developed as, 321
 - empathy training, 322
 - FRIENDS for Life, 322
 - description of, 323
 - fun FRIENDS program, 322
 - future research directions, 325–326
 - my youth FRIENDS, 322
 - protocols, 321
 - resilience for life, 322
 - significant revisions, 322
 - unique aspect, 322
 - universal prevention, 324
- Frost multidimensional perfectionism scale
- correlational research, 163–166
 - measures, 165
 - mistakes subscale, 162
 - reductions, 180
 - scores, 180
 - subscales, 167
- Functional magnetic resonance imaging (fMRI)
- activation studies in social anxiety disorder
 - emotional face processing, 338–342
 - non-social negative emotional processing, 350–351
 - positive emotional processing, 350–351
 - resting state studies, 352–355
 - social interactions, 347–349
 - symptom provocation, 344–347
 - brain activity, adolescents, 261

- overview, 336
 specific brain regions, 720
- G**
- GABA. *See* γ -Aminobutyric acid
- Gabapentin, social anxiety disorder
 management, 645. *See also*
 Anticonvulsants
- GABAergic effects, 645
- GAD. *See* Generalized anxiety disorder
- Gaze anxiety rating scale (GARS), 64
- Generalized anxiety disorder (GAD)
 activation studies in social anxiety disorder
 emotion regulation, 343–344
 amygdala reactivity, 339
 benzodiazepines, anxiolytic properties of,
 641
 functional neuroimaging studies, 339
 positive event processing, 562
 rates of comorbid, 230
 scales, 59
 subjective anxiety symptoms, 262
 treatment of, 641
- Generalized social phobia (GSP), 29
- General social avoidance and inhibition
 (SAD-G), 66
- G protein-coupled receptors, 385
- H**
- Hewitt and Flett model, perfectionistic self-
 presentation, 169–172
- facet
- nondisclosure of imperfection, 169
 - nondisplay of imperfection, 169
 - perfectionistic self-promotion, 169
- interpersonal psychological distress, 169
- multi-faceted construct, 169
- perfectionistic self-presentation scale
 (PSPS), 169, 170
- sense of self-acceptance, 169
- HPA axis. *See* Hypothalamic – pituitary –
 adrenal axis
- Hypothalamic-pituitary-adrenal (HPA) axis
 abnormal 5-HT_{1A} binding, 358
 activation of, 407
 activity in social anxiety disorder,
 334–335
 circadian rhythm, 334
 dexamethasone suppression test, 334
 gland mediated cortisol, 513
 neuroactivehormones, 334
 social phobia patients, 334
- I**
- IBT. *See* Irrational beliefs test
- ICD. *See* International classification of
 diseases
- Individual differences, social anxiety disorder
 comorbidity. *See* Cross-cultural
 expressions, social anxiety
 disorder comorbidity
- International classification of diseases
 (ICD), 11
- social phobias, 11
 - structured interview based, 50
- International classification of diseases
 (ICD), social anxiety
 definition, 11
- Interpersonal therapy (IPT)
 BFNE scores, 683
 effects, SAQ, 668
 transcripts of therapists, 793
- Interpretation
- ambiguous social interactions, 490.
 (*See also* Ambiguous events
 interpretation)
 - bias, study of, 490
 - social anxious individuals (SAIs),
 490
 - social feedback, 490
 - inherent ambiguity, 490
- Interpretation bias, social anxiety treatment
 impact, 677–678
- consequences of negative social events
 questionnaire (CONSE-Q), 677
- Interpretation of positive events scale (IPES),
 562
- Inter-rater reliability
 diagnosis of SAD, 50
- Interview. *See* Clinical interview
- Interviewer-rated scales, social anxiety
 disorder, 51–52
- IPES. *See* Interpretation of positive events
 scale
- IPT. *See* Interpersonal therapy
- Irrational beliefs test (IBT), 667
- K**
- Karolinska scales of personality (KSP), 357
- detachment scale of, 357
 - detachment scores, 357
 - D₂ receptor density, 357
 - PET study, 357
- Kutcher generalized social anxiety scale for
 adolescents (K-GSADS-A), 67

L

- Levetiracetam, social anxiety disorder management, 646. *See also* Anticonvulsants
- Liebowitz self-rated disability scale (LSRDS), 52
- Liebowitz social anxiety scale for children and adolescents (LSAS-CA), 65
- Liebowitz social phobia scale (LSPS), 51 self-report format, 53
- Liebowitz social phobia scale-self-report (LSPS-SR), 53
 - clinician-administered LSPS, 53
 - correlated, 53
 - cut-off scores, 53
 - yield comparable means, 53
- LSAS-CA. *See* Liebowitz social anxiety scale for children and adolescents
- LSPS, Liebowitz social phobia scale. *See* Liebowitz social phobia scale
- LSPS-SR, Liebowitz social phobia scale-self-report. *See* Liebowitz social phobia scale-self-report
- LSRDS. *See* Liebowitz self-rated disability scale

M

- Magnetic resonance imaging (MRI). *See also* Functional magnetic resonance imaging
 - overview, 336
 - structural brain imaging in social anxiety disorder, 337
- Magnetic resonance spectroscopy (MRS), social anxiety studies
 - N*-acetylaspartate, 359
 - serotonin system, 357–358
- MAOIs. *See* Monoamine oxidase inhibitors
- MBSR. *See* Mindfulness-based stress reduction
- Melatonin, temperament role, 386–387
- Memory
 - social anxiety disorder studies, 495–500
- Mindfulness-based stress reduction (MBSR), emotion regulation interventions, 343–344, 522–523
- Mindfulness-based therapy, social anxiety disorder
 - evidence of interventions, 732–735
 - key components of, 731
 - task concentration, eight-week protocol allowing/letting be, session 5, 740

- awareness and automatic pilot, session 1, 737–738
 - awareness of body, session 2, 738–739
 - awareness of breathing, session 3, 739
 - general elements, 735–736
 - preparation, 736
 - staying in present moment, session 4, 740
- theory and experimental evidence, attentional processes, 730–732
- Mini-SPIN-R, social anxiety disorder measures, 58–59
- Mirtazapine. *See also* Antidepressants
 - children and adolescents use, 650
 - social anxiety disorder management, 640
- Moclobemide, social anxiety disorder management, 626–627
- Monoamine oxidase inhibitors (MAOIs)
 - pharmacologic treatments, 777
 - social anxiety disorder treatment
 - irreversible, nonselective inhibitors, 626–627
 - reverse monoamine oxidase-A inhibitors, 628–629. *See also* Reverse inhibitors of monoamine oxidase-A (RIMAS))
 - sources, 626
- Multi-dimensional anxiety scale for children (MASC), 67
- Mutism, anxiety disorders, 648

N

- NAA. *See* *N*-acetylaspartate
- N*-acetylaspartate (NAA), magnetic resonance spectroscopy studies in social anxiety disorder, 359
- Nefazodone, social anxiety disorder management, 641. *See also* Antidepressants
- Neurological activity, social anxiety treatment impact, 662–666

O

- Obsessive compulsive disorder (OCD), 57
- OFC. *See* Orbitofrontal cortex
 - Opioids, temperament role, 383
- Orbitofrontal cortex (OFC), neuroimaging in social anxiety disorder
 - structure, 336
- Overt behavioral performance, social anxiety subgroups, 693

- treatment impact, 686–690
 - behavioral ratings of performance quality, 688–690
 - escape and avoidance, 686–687
 - Oxytocin, temperament role, 383
- P**
- Paroxetine
 - children and adolescents use, 649
 - social anxiety disorder management, 635–636
 - PCC. *See* Posterior cingulate cortex
 - Perfectionism
 - definition, 159
 - discrepancy role, social anxiety
 - clinically diagnosed social phobia, trait perfectionism levels, 167–168
 - Hewitt and Flett model, 169–172
 - perfectionism cognitions, 172–174
 - extended model, 174–177
 - linking perfectionism with social anxiety, 160–162
 - research overview
 - correlational research, 163–166
 - role of discrepancy, social anxiety
 - feelings of dissatisfaction, 167
 - Hewitt and Flett model, perfectionistic self-presentation, 169–172
 - self-discrepancy model, 167
 - treatment implications, 178–181
 - cognitive behavioral therapy, 180
 - FMPS scores, 179
 - unidimensional vs. multidimensional
 - conceptualizations, 162
 - Perfectionistic self-presentation scale (PSPS)
 - incremental validity, 170
 - predictor block, 170
 - variance
 - social interaction anxiety, 170
 - Performance deficits, social anxiety
 - relationship, 12
 - Pergolide, 645
 - Personality disorders
 - association of social phobia, 34
 - DSM anxious personality disorder cluster, 34
 - Person perception, 606–607
 - impression formation, 606
 - clinical SAD individuals, 606
 - non anxious individuals, 606
 - interpersonal rejection, 606
 - people's social status
 - estimation of, 607
 - social anxiety disorder
 - individuals vs. non-anxious individuals, 606
 - rated protagonists, 606
 - PET. *See* Positron emission tomography
 - PFC. *See* Prefrontal cortex
 - Phenelzine, social anxiety disorder
 - management, 626
 - Phobic social situations, 48
 - list of, 48
 - Physiological symptoms, social anxiety
 - physiological reactors
 - wait-list condition, 663
 - positive face (AP), 665
 - positron emission tomography (PET), 665
 - pre-to-post treatment, 663
 - respiratory sinus arrhythmia (RSA), 664
 - self-instructional training, 666
 - skin conductance reactivity (SCR), 665
 - social effectiveness therapy (SET), 663
 - social skills training, 663
 - threatening face (AT), 665
 - treatment impact, 662–666
 - cognitive behavioral group therapy (CBGT), 662
 - educational-supportive therapy (ES), 662
 - physiological measures, 662
 - skin conductance reactivity, 662
 - wait list control (WLC), 665
 - Positive experiences/events
 - biological markers of diminished rewards
 - in social anxiety, 566–567
 - dopaminergic neurotransmission, 566
 - neurobiological circuitry, impaired, 566
 - impaired positive cognitions, social anxiety, 559–566
 - atypical post-event processing, positive information, 561–562
 - dearth of positivity, predicting, 564–565
 - lack of normative, positive self-evaluations, 562–564
 - positive evaluation fear, 563–564
 - life's perceived quality, lack of positive bias, 565
 - meaningful heterogeneity in social anxiety, 567–568
 - self-regulatory model, social anxiety, 555–559
 - emotion dysregulation, positivity deficit mechanism, 556–557
 - extreme self-awareness, 555

- Positive experiences/events (*cont.*)
 hyper-focused, 555
 impaired attention, positivity deficits
 mechanism, 558–559
 social anxiety and diminished positive
 experiences, 552–555
 depressive symptoms, 553
 experience-sampling studies, 554
 meta-analysis, 553
 posttraumatic stress disorder, 554
 single-occasion global questionnaire,
 554
 social relationships, 552
 treatment implications, 568–570
- Positron emission tomography (PET), 259
 activation studies in social anxiety disorder
 neuroanatomy, 336
 resting state studies, 352–355
 summary of studies, 356
 symptom provocation, 344–347
 brain profile, 408
 neurotransmitter system imaging in social
 anxiety disorder
 dopamine, 356–357
 serotonin, 357–358
 overview, 336
- Posterior cingulate cortex (PCC),
 neuroimaging in social anxiety
 disorder
 functional neuroimaging, 338, 352–355
 structure, 336
- Prefrontal cortex (PFC), 260–261
 amygdala connectivity, 262–262, 342
 functional overview, 336
 neuroimaging in social anxiety disorder
 functional neuroimaging, 338–340,
 346–351
 structure, 336
- Pregabalin, social anxiety disorder
 management, 645–646. *See also*
 Anticonvulsants
- Prevention programs, social anxiety disorder
 management
 coping and promoting strength program
 (CAPS), 321
 child anxiety prevention study,
 developed from, 321
 child components, 321
 cognitive-behavioral anxiety prevention
 program, 321
- FRIENDS programs (*See* FRIENDS
 prevention programs)
 future research directions, 325–326
 mental health concerns, 320
 preschool intervention project, 320
 anxious symptomatology, 320
 implementation, 320
 parent-education program, 320
 aim, 320
 psychoeducation, anxiety and risk
 factors, 320
- Prevention types, social anxiety, 317
 effective prevention program, 317
 key factors, 317
 levels of prevention, 317
 preventative intervention targets
 indicated, 317
 selective, 317
 universal, 317
- Protective factors, social anxiety development,
 314–316
 Erikson's psychosocial stages, 316
 familial transmission of anxiety, 315
 function mechanism, 314
 interpersonal relationships, 316
 parent-child attachment, 315
 disorganized, insecure attachment, 315
 positive attachments, development of,
 315
 stable, secure attachment, 315
 positive peer relationships, 316
 prosocial behaviors, 316
 social anxiety disorder
 susceptibility to, 315
 social networks, analysis of, 316
 socio-emotional competence, 314
 includes, 314
 socio-emotional skills, 315
 summary, 316
- PSPS. *See* Perfectionistic self-presentation
 scale
- Psychopharmacological treatment studies, 34
- Psychophysiological arousal, biological factor,
 263
- Psychophysiological assessment in social
 anxiety, 75–77
 anxiety-provoking stimuli, 75
 anxiety-related reactions, 75
 embarrassment, 75
 autonomic nervous system (ANS), 75
 parasympathetic system, 75
 sympathetic system, 75
 cardiovascular assessment, 76–77
 conducts, cognitive restructuring, 76
 electrodermal recordings, 77
 other physiological assessments, 77

- physiological data, 76
- social skills training, 76
- treatment decisions, 76
 - pharmacological treatment, 76
- Psychosis, social anxiety disorder comorbidity, 241
- Psychosocial treatments, mechanisms of
 - action in social anxiety disorder, 792–793

Q

- Quetiapine, social anxiety disorder management, 647

R

- Reboxetine, social anxiety disorder management, 641. *See also* Antidepressants
- Regulator of G-protein signalling (RGS2), 383
- Respiratory sinus arrhythmia (RSA), 664
 - higher levels of resting, 664
 - measure
 - anticipation of a speech task, 664
 - withdrawal, 664
- Reverse inhibitors of monoamine oxidase-A (RIMAS), social anxiety disorder management
 - brofaromine, 629
 - moclobemide, 628–629
 - treated patients, 628
 - vs. monoamine oxidase inhibitors (MAOIs), 628
- Revised children's manifest anxiety scale (RCMAS), 67
- RGS2. *See* Regulator of G-protein signalling
- RIMAS. *See* Reverse inhibitors of monoamine oxidase-A (RIMAS)
- Role-playing procedures, social anxiety
 - role-play test (RPT), 69–71
 - social anxiety and phobia assessment, 69–71
 - simulated social interaction test (SSIT), 71–72
- RPT. *See* Role-play test
- RSA. *See* Respiratory sinus arrhythmia

S

- SAD. *See* Social anxiety disorder
- SADS. *See* Social avoidance and distress scale
- Scale for interpersonal behavior (SIB), social skill assessment in social phobia, 195

- Schizoid personality cluster, 34
- Screen for child anxiety related emotional disorders (SCARED), 67
- Selective serotonin reuptake inhibitors (SSRIs)
 - children and adolescents use, 648–650
 - controlled trials, 629
 - social anxiety disorder management
 - citalopram, 637–638
 - escitalopram, 637–638
 - fluoxetine, 638–639
 - fluvoxamine, 638
 - paroxetine, 635–636
 - sertraline, 636–637

Self

- behavioral strategies, 540
- cognitive processing (. *See* Self-referent cognitive processing)
- concept clarity, 542
- definition, 531
- organization, 541–542
 - evaluative, 541
- related concepts, 531
- related motives, 540
 - approaches, 540
- schema content (*See* Self-schema content)
- social cognitive perspective, 532
 - issues, examined, 532
- structure, 541
 - refers to, 541
- Self efficacy for social situations scale (SESS), 68
- Self-monitoring, social anxiety and phobia, 72
- Self-presentation theory
 - interpersonal behavior and social anxiety, 589–590
 - original theory
 - empirical support, 580
 - evidence for, 583
 - fundamental proposition, 580
 - original theory, 580–583
 - self-presentational perspective, 582
 - socially anxious people, 581
 - virtue of, 580
 - sociometer theory as extension
 - link to self-presentation, 587–588
 - overview, 583–584
 - social anxiety as sociometer, 585–587
 - treatment implications, 590–592
 - antecedents of trait social anxiety, 590–591
 - treating social anxiety disorder, 591–592
 - treating trait social anxiety, 591–592

- Self-referent cognitive processing
 - judgment biases, 538
 - social anxious individuals, 538
 - post-event processing (PEP), 538, 539
 - processes, links between, 539
 - rumination, post-event, 538
 - selective attention, 536–539
 - consciousness, self, 536
 - focused attention, self, 537
 - threat-related external cues, 537
- Self-schema content
 - efficacy, self, 536
 - definition, 536
 - esteem, self, 535
 - images, self, 534–535
 - negative self-images (NSI), 534
 - positive self-imagery, 535
 - related thoughts, self, 532–533
 - maladaptive self-beliefs, 533
 - core extrusion schema (CES)
 - measure, 533
 - social comparison, 533
 - social ineptness, 533
 - types, 533
 - negative self-statements, 532
 - positive self-statements, 532
- Self-statements during public speaking scale (SSPS), 74
- Septohippocampal system
 - medications, 790
- Serotonin
 - activity duration, 381
 - neuroimaging in social anxiety disorder, 357–358
 - secretion, 381
 - temperament role, 381
- Serotonin norepinephrine reuptake inhibitors (SNRIs)
 - social anxiety disorder management
 - duloxetine, 640
 - venlafaxine, 639–640
- Sertraline
 - children and adolescents use, 648–650
 - social anxiety disorder management, 636–637
 - treated patients vs. placebo-treated patients, 636
- SET. *See* Social effectiveness therapy
- Sheehan disability scale (SDS), 52
- Shyness
 - affective features, 107
 - behavior, 98, 107–108
 - characteristics of, 104–109
 - children behavior, 421
 - chronic shyness, 98
 - development, 100–103
 - fear of negative evaluation, 98
 - cognitive features and perception, 105–106
 - definitions, 99
 - egocentric preoccupation, 98
 - emotional component, 98
 - emotional states, 99
 - family characteristics, 108–109
 - heterogeneous, 99
 - impairment, assessment, 99
 - interest, 98
 - prevalence, 100
 - self-reported traits, 99
 - social phobics, 98
 - somatic symptoms, 104–104
 - treatment, 99
 - vs. social phobic individuals, 103–104
- SIB. *See* Scale for interpersonal behavior
- Simulated social interaction test (SSIT)
 - social anxiety and phobia assessment, 200–201
- Single nucleotide polymorphisms (SNPs)
 - ADHD, 400
 - autism, 400
 - bipolar disorder, 400
 - schizophrenia, 400
 - temperament role, 385–386
- Single photon emission computed tomography (SPECT)
 - dopamine system imaging in social anxiety disorder, 356–357
 - functional neuroimaging in social anxiety, 352
 - overview, 336
- SISST. *See* Social interaction self-statement test
- SNPs. *See* Single nucleotide polymorphisms
- SNRIs. *See* Serotonin norepinephrine reuptake inhibitors
- Social anxiety
 - cultural dimensions, impact, 146–149
 - individualism and collectivism, 146–148
 - self-construal, 149
 - cultural variations, 150
 - definitions, 8–9
 - prevalence, across countries, 142–146
- Social anxiety disorder (SAD), 27
 - analysis of
 - observable behaviors, 19
 - anxiety-provoking situations, 651

- anxious symptomology continuum, 312
 - characteristics of, 312
- avoidant disorder of childhood and adolescence (AVD), 254
- avoidant personality disorder comparison
 - (*See* Avoidant personality disorder)
- body dysmorphic disorder, 4
- comorbidity rates, using DSM-IV criteria
 - current, 236–237, 238
 - lifetime, 232–233, 235
- core features, 612
 - conceptualization of, 612
 - multi-modal communication, examination of, 612
- development of, 312–319
 - anxious symptomology (*See* Anxious symptomology, risk factors in development of)
 - preventative interventions, 312
 - protective factors (*See* Protective factors, social anxiety development)
- differences in, 6
- DSM-5 alteration, 254
- early intervention, 317
 - summary, 319
- evidence, 40
- forms, 12–15
- generalized version of, 29
- general social anxiety, distribution, 7
- history, 254–256
- lifetime prevalence of, 8
- lower scores, 6
- milder variant, 40
- model, 778–780
- morphology, 254–256
- negative evaluation, social/performance fear, 254
- pathological extremes, 19
- pharmacotherapy and cognitive
 - behavioral therapy, combined, 790
- prevalence rate, social phobia, 142–146, 256
- prevention, 317. (*See also* Anxiety prevention; Prevention types, social anxiety)
- prevention programs, implementing
 - challenges, 318
 - difficulties set, 318
 - evaluation of, 318
- prime target for, 312
- psychological treatment, across cultures, 152–153
- social nature, 19
- subgroups, 693
 - rational-emotive therapy, 693
- subtypes, types of, 12
 - public speaking, 13
- suicidality, comorbidity, 241–242
- symptoms
 - impact of, 312
- theory and experimental evidence, 730–732
- treatment implications, 613
 - cognitive-behavioral interventions, 613
 - interpersonal interventions, 613
 - status-enhancing interventions, 613
 - thin-skinnedness, 613
- Social anxiety disorder dimensional scale (SAD-D), 59
- Social anxiety evolutionary models, two
 - biobehavioral systems, 601–603
- adaptive function, social anxiety, 602
- dominance-submissiveness system, 601
- Leary's account, 602
- self-awareness, heightened, 602
- social anxiety characterization, 602
- social cautiousness, 602
- socially anxious individuals, 602
- submissive
 - behaviors, 602
 - gestures, 601
- symbolic gestures
 - dominance, 601
- Social anxiety scale for children (SASC-CA), 66
- Social anxiety screening questionnaire (SAS-Q)
 - sample, 52
- Social anxiety session change index (SASCI), 59
- Social avoidance and distress scale (SADS), 6, 61–62
- Social backdrop, social anxiety, 96–97
- Social effectiveness therapy (SET), 663
- Social factors, social anxiety
 - parenting style, 270–272
 - peer influence, 272–274
- Social fitness training, social anxiety and shyness
 - cognitive-emotional self-regulation, 109
 - compassion focused therapy approach, 110–111
 - egalitarian behavior, 109
- Social interaction anxiety scale (SIAS), 55

- Social interaction self-statement test (SISST), 73–74, 671–672
- Social life, evolutionary perspective
 evolutionary models (*See* Social anxiety evolutionary models, two biobehavioral systems)
 group living, humans, 599
 advantages, 599
 two-biobehavioral systems, 600
 affiliation, 600. (*See also* Affiliation biobehavioral system (ABS))
 social rank, 600. (*See also* Social rank biobehavioral system (SRBS))
- Socially anxious individuals (SAIs), 47
- Social performance survey schedule (SPSS),
 social skill assessment in social phobia, 195–198
- Social phobia. *See* Social anxiety disorder
- Social phobia anxiety inventory (SPAI), 53–55
 for children (SPAI-C), 65
- Social phobia inventory (SPIN), 57–58
- Social phobia scale, 56
- Social phobic inventory in adolescents, 67
- Social rank biobehavioral system (SRBS), 600
 estradiol
 female social rank and dominance, 601
 humans social rank, processing of, 600
 social competition, 600
 social hierarchies, 600
 stable social organization, 600
 testosterone, biochemical substrate related to, 601
- Social self-efficacy and self-esteem in adolescents, measures of, 68
- Social skills
 aim and method, 190
 assessment, socially phobic, 194–195
 behavioral measures, 202–203
 definition, 191
 hypothesis, 191
 improvement in performance, 214–215
 notion of, 191
 self-protective shell, 215
 self-reports, 195–198
 skills deficits, 191, 203–215
 deficient, socially phobic sub-groups, 210–211
 socially anxious individuals, 203
 social functioning, social phobia problem, 216–217
 training, 211–214, 791
 treatment, social phobia, 218–220
 views, 193–194
 inter-personal view, 194
 intra-personal view, 193
- Social skills questionnaires (SSQ-P), 66
- Social status changes, responses to
 pride, 609–610
 effects of social anxiety, 609
 self-conscious emotion, 609
 social anxious individuals, 610
 social power/leadership, 609
 cortisol high levels, 609
 insulating effects, social anxiety, 609
 psychological benefits of, 609
 testosterone high levels, performance, 609
 social status loss
 defeat, 608
 humiliation, 608
 shame, 608
- Spence children's anxiety scale (SCAS), 67
- SPIN/mini-SPIN in adolescents, 67
- SPSS. *See* Social performance survey schedule
- SRBS. *See* Social rank biobehavioral system
- SSIT. *See* Simulated social interaction test
- SSPS. *See* Self-statements during public speaking scale
- SSRIs. *See* Selective serotonin reuptake inhibitors
- Stress response, social anxiety disorder findings, 334–335
- Structured clinical interview for DSM-IV (SCID-IV), 48
- Subjective probabilities, social anxiety
 treatment impact, 674–676
 individual cognitive therapy, 675
 overestimations, likelihood, 674
 subjective probability scale, 674
 treatment effects, 674
 within-group effect sizes, 674
- ## T
- Temperament
 assessment
 biological measures, 427–430
 high-reactives, 429
 low-reactives, 429
 cascades and mental states, 435–436
 eighteen year old, 432–434
 clinical symptoms, 434–435
 eleven years, 427
 fifteen years, 430–432
 biological measures, 432–434

- four-and-a-half-years, 425–426
 - second year, 424–425
 - seven-and-a-half-years, 426
 - visceral feedback, 436–437
 - categories
 - high-reactivity, 439–441
 - low-reactivity, 439–441
 - determinism/limitations, 437–439
 - enthusiasm for biology, 392–412
 - American vs. Japanese psychiatrists, 405
 - anatomical interconnectivity, 405
 - antisocial behavior, origin of, 400
 - blood flow pattern, adults, 406
 - brain metrics, 411
 - brain, psychological phenomena
 - foundation, 408
 - cause of saccade, 407
 - cerebral blood flow in humans, studies of, 401
 - childhood adversities, 399
 - contemporary films, 404
 - copy number variant (CNV), 405
 - depression bouts, high prevalence of, 402
 - emotions, adults, 393
 - emotions muting, 403
 - evolution, factors responsible for, 409
 - friendlessness, 402
 - general adaptation syndrome, 396
 - Hispanic children, 398
 - human actions, 407
 - human aesthetic evaluation of music, 409
 - human psychonome project, 411
 - idiosyncratic, 393
 - immune system, ability of, 397
 - intuitionpopular theory, 410
 - Niels Bohr's principle, 409
 - Pavlov, 399–400
 - physical exercise, therapeutic effects, 393
 - psychologically stressful events, 396
 - psychological process, emergence of, 407
 - psychological stressor, 397
 - reluctance to blame victims, 398
 - sense of control, 395
 - stress, 396–397
 - symbolic world, properties of, 402
 - sympathy level, increasing, 403
 - unconditioned reflexes, 399
 - unhappiness, 402
 - world's problems, nature of, 393
 - evidence sources in bias determination, 387–392
 - Lab-TAB, behavioral observations, 388
 - genes and neurochemistry, 380–386
 - dopamine, 384
 - gamma-aminobutyric acid (GABA), 383
 - heritability coefficients, 386
 - neuromodulators, 380
 - neuropeptides, 383
 - neurotransmitters, 380
 - serotonin, 381
 - infants
 - high-reactive, 421–424
 - low-reactive, 421–424
 - temperamental biases, 420
 - inhibited children, 420
 - reactions to the unfamiliar, 419–420
 - response uncertainty, 419
 - types, 378–380
 - behavioral phenotype, 379
 - temperamental biases, 378
 - uncertainty-evoking events, 420
 - Test-retest reliability
 - DSM-IV ADIS-C/P diagnoses, 50
 - Thought-listing and thought-recalling, social anxiety disorder, 74–75
 - Thought-listing, social anxiety and phobia assessment, 73–75
 - Tiagabine, social anxiety disorder management, 647. *See also* Anticonvulsants
 - Tier social stress test (TSST)
 - anxiety trait, measurement of, 732
 - social anxiety disorder findings, 335
 - Topiramate, social anxiety disorder management, 646. *See also* Anticonvulsants
 - Tranlycypromine, social anxiety disorder management, 627
 - Tricyclic antidepressants, 641. *See also* Antidepressants
 - TSST. *See* Trier social stress test
- ## V
- Valporic acid, social anxiety disorder management, 647. *See also* Anticonvulsants
 - Venlafaxine
 - children and adolescents use, 650
 - social anxiety disorder management, 639–640

Virtual sphere, self-presentation, 607–608
 computer-mediated communication,
 607
 Facebook profiles
 objective measures of, 607

face-to-face communication, 607
 non-verbal cues
 substitution of, 607
 social sites' profiles, 607
 social structures, 607